Home
Home » Monthly archive

November 2011

Novartis MS Pill Gilenya Rejected by U.K. Health-Cost Agency

Novartis MS Pill Gilenya Rejected by U.K. Health-Cost Agency
Bloomberg

Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity

Savient Pharmaceuticals: Sluggish Launch Of Krystexxa Presents Buying Opportunity
Seeking Alpha

A Simple Plan (to Save US Pharma Manufacturing)

A Simple Plan (to Save US Pharma Manufacturing)
Pharm Exec

Hospira's production woes widespread, analyst says

Hospira's production woes widespread, analyst says
Fierce Pharma

Pfizer and Merck May Benefit From Spinoffs, Goldman Sachs Says

Pfizer and Merck May Benefit From Spinoffs, Goldman Sachs Says
Bloomberg

Two Top Biotech Plays With Safe Upside

Two Top Biotech Plays With Safe Upside
Seeking Alpha

Why the Street Should Love Merck's Earnings

Why the Street Should Love Merck's Earnings
Motley Fool

Rivals threaten to take wind from Watson’s generic Lipitor sales

Rivals threaten to take wind from Watson’s generic Lipitor sales
Med City

Pfizer After Lipitor to Push Mini-Blockbusters

Pfizer After Lipitor to Push Mini-Blockbusters
Bloomberg

Why There Will Never Be Another Drug Like Lipitor

Why There Will Never Be Another Drug Like Lipitor
Forbes